Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
NCT ID: NCT05249959
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
49 participants
INTERVENTIONAL
2022-03-21
2029-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
NCT03684694
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
NCT04998669
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT03589469
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
NCT02558816
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
NCT03685344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Objective:
\- To assess the efficacy of a consolidation with loncastuximab tesirine following salvage immunochemotherapy (2 courses of Rituximab-Bendamustine-Cytarabine, R-BAC) in Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphomas (MCL).
Secondary Objectives:
* To evaluate the safety profile of loncastuximab tesirine consolidation.
* To assess the rate of Minimal Residual Disease (MRD) negativity after loncastuximab tesirine consolidation.
R/R MCL patients after one, two, three or four lines of treatment including BTKi treatment (or BTKi intolerant), with complete response (CR) or partial response (PR) or with stable disease (SD) after salvage immunochemotherapy (R-BAC x 2, Rituximab - Bendamustine, Cytarabine) will undergo consolidation with loncastuximab tesirine. A patient with CR, PR or SD after one R-BAC course, which is unable to undergo a second course due to toxicity to chemotherapy, can be considered to proceed for consolidation.
After checking inclusion and exclusion criteria and signing written informed consent, patients will be enrolled in the study, and the system will assign them an alphanumeric code that will identify the patient in every study procedure.
Efficacy parameters will be evaluated according to the Lugano 2014 Classification.
Toxicity parameters will be evaluated according to the definitions of the current version of the NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) criteria.
After treatment discontinuation, both in the case the protocol treatment was fully administered and in the case of an early discontinuation, patients will be followed-up according to clinical practice timeline and procedures, and information on patient status (progression/relapse, alive/dead, lost to follow-up) will be collected till the end of the study (LPLV), planned 36 months after the start of treatment of the last patient enrolled in the study. In case of progression/relapse during follow-up, the patients will be then followed-up for survival till the study end.
49 patients will be enrolled in the study.
The anticipated study dates are:
* Total accrual period: 48 months
* Last patient last visit (LPLV): 36 months after the start of treatment of the last patient enrolled.
The study will include a period of screening up to 21 days, a period of treatment of up to 22 weeks and a follow-up period with visits every 4-8 weeks for the first year after study entry and then every 8-12 weeks for at least 2 years.
Treatment includes a period of induction with 2 cycles of 28 days with R-BAC (=8 weeks) + two/four weeks for restaging + 4 doses of loncastuximab tesirine every 21 days (=12 weeks), i.e., a total period of 22 weeks, for patients who achieved CR, PR or SD after salvage immunochemotherapy. A follow-up period with visits every 4-8 weeks for the first year after study entry and then every 8-12 weeks for at least to 2 years.
For the study is also planned an extended follow-up after the end of the study requiring participating sites to provide only information on patient status (alive, dead, lost to follow-up) and to record possible events occurred after the end of the study, including diagnosis of second neoplasia and long-term toxicity for additional 2 years after the end of the study.
Disease evaluation will be performed initially (Baseline Assessment), after the beginning of treatment with R-BAC (End of Induction), at the end of loncastuximab tesirine consolidation phase (End of Treatment) and then every 6 months during the follow-up period.
Non-responder, relapsing or progressive patients will be treated according to best clinical practice.
Treatment schedule:
Standard Induction phase:
2 courses of R-BAC every 28 days according to the following schedule
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 70 mg/m2, Days 2 and 3
* Cytarabine 500 mg/m2, Day 2-4
Reduced Induction phase:
For patients deemed FRAIL or UNFIT for standard induction therapy (based on protocol dose and as per medical judgment), reduced R-BAC options may be considered. For patients \> 80 years old the reduced induction schedule is recommended.
Two different schedules will be allowed
Cycle 1-2
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 70 mg/m2, Days 2 and 3
* Cytarabine 500 mg/m2, Day 2 and 3
or
Cycle 1-2
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 100 mg, Days 2 and 3
* Cytarabine 500 mg, Day 2 and 3
An optional pre-phase with steroid (prednisone 1 mg/kg/day, maximum of 7 days before starting induction phase) and/or single dose of Vincristine (up to 2 mg total) was allowed.
After restaging at the End of Induction (EOI) patients with CR, PR or SD will receive:
CONSOLIDATION PHASE:
* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg\* every three weeks followed by
* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg\* every three weeks
* (For patients with BMI\> 35 dose will be calculated based on adjusted weight). Patients will undergo initial staging with CT (Computed Tomography) scan, PET (18F-FDG Positron Emission Tomography)/PET-CT scan and bone marrow (BM) biopsy. Patients will be fully restaged after induction (EOI), after loncastuximab tesirine consolidation (EOT) and then every six months only with CT-scan.
Tumour re-biopsy will be performed only if clinically indicated. Bone Marrow (BM) and Peripheral Blood (PB) samples for MRD evaluation purposes will be taken at the same time points when CT-scan is done (to be performed centrally at certified Euro-MRD academic laboratories, according to Euro-MRD guidelines).
Response to treatment will be evaluated according to the Lugano 2014 criteria. Based on published results we considered the expected 12-month PFS with available treatments to be \<20%; we hypothesized that, in this setting of patients, a consolidation with loncastuximab tesirine (ADCT-402) may increase the expected 12-month PFS to ≥40% According to one arm non-parametric survival provided by SWOG (Southwest Oncology Group-NCI), with an alpha error (one sided) equal to 0.05, a beta error equal to 0.10, 2-years of accrual and a minimum of 3 year of follow-up, the required sample size consist of 49 patients who start treatment after screening phase. The lower limit of the 90% confidence interval (according to 1-sided alpha error of 0.05) of the 12-month PFS must be higher than the null hypothesis of 0.20 to conclude that the new treatment is promising for a subsequent phase III study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy
R/R MCL after one, two, three or four lines of treatment including BTKi treatment (or BTKi intolerant), with complete response (CR) or partial response (PR) or with stable disease (SD) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C x 2 cycles) will undergo consolidation with loncastuximab tesirine. A patient with CR, PR or SD after one R-BAC course, which is unable to undergo a second course due to toxicity to chemotherapy, can be considered to proceed for consolidation.
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 70 mg/m2, Days 2 and 3
* Cytarabine 500 mg/m2, Day 2-4
After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:
CONSOLIDATION PHASE:
* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by
* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 70 mg/m2, Days 2 and 3
* Cytarabine 500 mg/m2, Day 2 and 3
or
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 100 mg, Days 2 and 3
* Cytarabine 500 mg, Day 2 and 3
After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:
CONSOLIDATION PHASE:
* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by
* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 70 mg/m2, Days 2 and 3
* Cytarabine 500 mg/m2, Day 2-4
After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:
CONSOLIDATION PHASE:
* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by
* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 70 mg/m2, Days 2 and 3
* Cytarabine 500 mg/m2, Day 2 and 3
or
* Rituximab 375 mg/m2 i.v. Day 1
* Bendamustine 100 mg, Days 2 and 3
* Cytarabine 500 mg, Day 2 and 3
After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:
CONSOLIDATION PHASE:
* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by
* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 and \< 85 years
* Relapsed/Refractory disease after one, two, three or four lines of treatment
* Bendamustine-naive or relapsed after at least one year after the last cycle of a bendamustine-containing regimen
* Previous treatment with BTKi (Bruton Tyrosine Kinase inhibitors) monotherapy or BTKi containing regimens with R/R disease; and/or patients who discontinued BTKi monotherapy or BTKi containing regimens for adverse events and have active disease necessitating treatment.
* Previous treatment with any anti-CD19 agents is allowed (included CAR-T treatment) If previous anti-CD19 treatment has occurred, tissue CD19 expression must be assessed by histology or flow cytometry
* Venetoclax treated patients are allowed.
* Stem cell transplant eligible patients are allowed.
* Measurable nodal or extranodal disease ≥ 1.5 cm in longest diameter, and measurable in 2 perpendicular dimensions. Note: Patients with bone marrow involvement only are eligible. In case of bone marrow infiltration only, bone marrow aspiration and biopsy are mandatory for all staging evaluations
* ECOG (Eastern Cooperative Oncology Group)/WHO (World Health Organization) performance status ≤ 2 (unless MCL-related)
* The following laboratory values at screening (unless due to bone marrow involvement by lymphoma):
* Absolute Neutrophil count (ANC) \> 1.0×109/L
* Platelet count ≥ 75.000/mm3
* Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)
* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN (upper limit of normal)
* Bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non- hepatic origin)
* Subject understands and voluntarily signs an informed consent form approved by an Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures.
* Subject must be able to adhere to the study visit schedule and other protocol requirements.
* Life expectancy ≥ 3 months.
* Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active.This applies for the time period between signing of the informed consent form and at least 10 months after last loncastuximab tesirine (ADCT-402) dose. Men with female partners who are of childbearing potential must agree to use effective contraception if sexually active. This applies for the time period between signing of the informed consent form and at least 7 months after last loncastuximab tesirine (ADCT-402) dose.
Exclusion Criteria
* Known history of hypersensitivity to human antibodies.
* Allogenic stem cell transplant within 6 months prior to start of first study drug.
* Allogenic stem cell transplant with active / uncontrolled graft-versus-host disease.
* Previous treatment with CD19 targeting agents.
* More than four lines of previous treatment (autologous stem cell transplant performed as part of consolidation to a previous line of therapy should not be considered as a line of therapy).
* Active second malignancy in the last three years other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or any other tumor that the Sponsor and Coordinating Investigator agree and document should not be considered preclusive to participate in the study.
* Major surgery or any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, investigational therapy, including targeted small molecule agents within 14 days prior to start of study drug (R-BAC). A shorter interval in special settings must be approved by the Sponsor and/or Investigator.
* Cardiovascular disease (NYHA, New York Heart Association, class ≥2).
* Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent.
* Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
* Uncontrolled and/or active systemic infection (viral including COVID 19, bacterial or fungal);
* Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note:
subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV DNA) are eligible. Patients with presence of HCV antibody are eligible only if PCR results (polimerase chain reaction) negative for HCV RNA.
* HIV seropositivity.
* Lymphoma with active CNS (central nervous system) involvement at the time of screening, including leptomeningeal disease.
* Congenital long QT syndrome or a corrected QTcF interval of \>480 msec at screening (unless secondary to pacemaker or bundle branch block).
* Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the patient inappropriate for study participation or put the patient at risk.
* If female, the patient is pregnant or breast-feeding.
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Italiana Linfomi - ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco Ladetto
Role: PRINCIPAL_INVESTIGATOR
S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo" di Alessandria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ASST Spedali Civili di Brescia
Brescia, Italy, Italy
S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Cesare Arrigo"
Alessandria, , Italy
S.C. di Ematologia - A.O. S. Croce e Carle
Cuneo, , Italy
Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi
Florence, , Italy
Ematologia - Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia
Genova, , Italy
Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, , Italy
S.C. Ematologia - ASST Grande Ospedale Metropolitano Niguarda
Milan, , Italy
UOC Ematologia Oncologica - Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale
Napoli, , Italy
SCDU Ematologia - AOU Maggiore della Carità di Novara
Novara, , Italy
Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello
Palermo, , Italy
Divisione di Ematologia - IRCCS Policlinico S. Matteo di Pavia
Pavia, , Italy
Ematologia - Ospedale delle Croci
Ravenna, , Italy
Ematologia - Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova
Reggio Emilia, , Italy
U.O. di Ematologia - Ospedale degli Infermi di Rimini
Rimini, , Italy
Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia
Roma, , Italy
U.O. Ematologia - Istituto Clinico Humanitas
Rozzano, , Italy
S.C. Ematologia Universitaria - A.O.U. Città della Salute e della Scienza di Torino
Torino, , Italy
S.C di Ematologia - Ospedale Ca Foncello
Treviso, , Italy
U.O.C Ematologia e Trapianto - A.O. C. Panico
Tricase, , Italy
SC Ematologia - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
Trieste, , Italy
U.O. Ematologia - AOU Integrata di Verona
Verona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIL_COLUMN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.